One Patient's last hope: stem cells for rare nerve disease

NCT ID NCT04825626

NO_LONGER_AVAILABLE Disease control Sponsor: Hope Biosciences Research Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gives one patient with CIDP access to their own stored stem cells to see if it's safe and might help. The patient receives multiple infusions over 44 weeks and is followed for a year. Because it's only one person, the results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous adipose-derived mesenchymal stem cells (HB-adMSCs)
What this could lead to: If it works, this could point toward a treatment for CIDP that reduces symptoms and improves nerve function.
What could go wrong: This is a single-patient expanded access program, not a controlled trial, so results may not apply to others. Risks include infection or lack of benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

Contacts and locations

Locations

Hope Biosciences Stem Cell Research Foundation

Sugar Land, Texas, 77478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.